Strategies for Continued IRT Success During COVID-19 Date Published: Jun 24, 2020 Article Featured in Journal for Clinical Studies, this article discusses the challenges IRT customers face with the recent COVID-19 pandemic and how to mitigate these potential issues to avoid interrupting ongoing clinical trials. Discover best practices for: Distribution challengesScreening & enrollment challengesA properly configured and adaptive IRT system can enable organizations to remain flexible and agile enough to face any challenge. Signant Health’s team of IRT designers, developers, supply experts, and statisticians are available to consult on challenges and best practices. Download Now Share: LinkedIn0Tweet0 Recommended Resources Article Putting Participants and Study Partners FIRST When Clinical Trials End Early When clinical trials end early, what happens to study participants and their study partners? A committee of researchers – including... Download Now Article The Continuum of the Clinical Trial Participant Experience The clinical research industry has evolved over the past decade with the adoption of new digital technology integrations that help... Read Article Article A New Approach to Diagnosing and Treating Major Depressive Disorder Can a blood test predict treatment response to antidepressants? Recent research conducted by Signant’s scientific director, Steven Targum, M.D., along... Download